Dephosphorylation of the Proneural Transcription Factor ASCL1 Re-Engages a Latent Post-Mitotic Differentiation Program in Neuroblastoma. by Ali, Fahad R et al.

 1 
Dephosphorylation of the proneural transcription factor ASCL1 re-engages a latent 














, Laura M. Woods
1,2




















Department of Oncology, University of Cambridge, Cambridge, UK 
 
2
Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, 
Cambridge Biomedical Campus, Puddicombe Way, Cambridge, UK 
 
3
College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, 
Dubai, United Arab Emirates 
 
4
Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, 








Running Title: ASCL1 dephosphorylation drives neuroblastoma differentiation 
Financial Support 
Work was supported by Cancer Research UK Programme Grant RG91505 (AP), Wellcome 
Trust Investigator Award 212253/Z/18/Z (AP), MRC Research Grant MR/L021129/1 (F.A, 
A.P); Neuroblastoma UK (D.M, T.P, A.P), CRUK Cambridge Centre Paediatric Programme 
(L.P), The Terry Fox Foundation (FA), MBRU College of Medicine Internal grant award 
MBRU-CM-RG2019-14 (FA), MBRU-ALMAHMEED Collaborative Research Award 
ALM1909 (FA) and core support from the Wellcome Trust and the MRC Cambridge Stem 
Cell Institute (F.A, D.M, J.D., A.P.) and Cancer Research UK Cambridge Insititute (I.C, J.C). 
 
Conflict of interest 
The authors declare no competing interests. 
 2 
Abstract  
Paediatric cancers often resemble trapped developmental intermediate states that fail to 
engage the normal differentiation programme, typified by high-risk neuroblastoma arising 
from the developing sympathetic nervous system.  Neuroblastoma cells resemble arrested 
neuroblasts trapped by a stable but aberant epigenetic programme controlled by sustained 
expression of a core transcriptional circuit of developmental regulators in conjunction with 
elevated MYCN or MYC (MYC). The transcription factor ASCL1 is a key master regulator in 
neuroblastoma and has oncogenic and tumour suppressive activities in several other tumour 
types. Using functional mutational approaches, we find that preventing CDK-dependent 
phosphorylation of ASCL1 in neuroblastoma cells drives co-ordinated suppression of the 
MYC-driven core circuit supporting neuroblast identity and proliferation, while 
simultaneously activating an enduring gene programme driving mitotic exit and neuronal 
differentiation.  
Implications: These findings indicate that targeting phosphorylation of ASCL1 may offer a 




 Neuroblastoma tumour cells resemble malignant neuroblastic developmental 
intermediates trapped epigenetically in a precursor-like state (1). In common with other 
childhood tumours that arise from aberrant proliferation of developmental intermediates, 
reactivation of a latent developmental programme of mitotic exit and differentiation may 
provide a promising therapeutic approach (2); for instance, reactivation of differentiation in 
the paediatric malignancy acute promyelocytic leukaemia has transformed the outcome of 
this disease from a frequently fatal disease to one with a 90% cure rate (3). Directed 
reactivation of tumour cell differentiation requires an understanding of the molecular 
mechanisms that cause stalling of normal development and an ability to reverse that stalling.   
 
 In neuroblastoma, recent studies have supported a model of aberrant epigenetic 
control that locks cells in a progenitor-like state via a network of super-enhancers; genes 
associated with an early developmental and proliferative programme are highly expressed 
because of associated and mutually regulated oncogenic super-enhancers (4-8).  High level of 
expression of these genes is maintained by elevated super-enhancer-associated MYCN or c-
MYC particularly in disease with poor prognosis. While collapse of this super-enhancer 
network by targeting transcriptional CDKs can lead to neuroblastoma cell death (9), 
reactivating the normal developmental processes in neuroblastoma cells is likely to require a 
more directed approach and modulation of the activity of transcriptional regulators that 
usually control these processes during development. One such regulator is ASCL1, a bHLH 
proneural transcription factor that plays a central role in noradrenergic neuron differentiation.  
 ASCL1 regulates both neural stem cell maintenance and differentiation during 
embryonic development (10), while its expression can be  associated with cancer “stem-ness” 
in glioblastoma (11, 12), small cell lung carcinoma (13), medulloblastoma (14) and 
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neuroblastoma (15-17). Conversely in glioblastoma, enhancing ASCL1 activity by Notch 
inhibition is sufficient to promote cell cycle exit and attenuate tumourigenicity (12). 
Therefore, evidence from the developing and adult central nervous system as well as 
glioblastoma indicates that ASCL1 levels, and therefore activity, may be critical for 
determining whether ASCL1 supports stem/progenitor maintenance or drives differentiation 
(10, 12).   
 
 Building on our understanding of the regulation of ASCL1 protein in normal 
development (15, 18), here we show that preventing ASCL1 phosphorylation in 
neuroblastoma cells results in cell cycle exit by direct suppression of the neuroblastic core 
regulatory circuit and the target genes that drive cell cycle progression. Alongside a 
supression of this pro-proliferative programme, we find that un(der)phosphorylated ASCL1 
simultaneously activates expression of the CDK inhibitor CDKN1C as well as genes 
associated with neuronal differentiation and function, driving mitotic exit and morphological 
maturation. Thus, we show that post-translational activation of a key developmental regulator 
in cancer cells can unmask latent tumour suppressive activity, inhibiting proliferation and 
promoting differentiation. 
 
Materials and Methods 
Cell lines 
The Neuroblastoma cell line SH-SY5Y was kindly gifted by Prof. John Hardy, UCL, and the 
SK-N-BE(2)c cell line was kindly gifted by Prof. Deborah Tweddle, Newcastle University. 
Cells were verified by submitting genomic DNA for short tandem repeat (STR) sequencing 
and compared to the Children’s Oncology Group Cell Line Identification database 
(http://www.cogcell.org/clid.php) to ensure it was genetically matched to standardised cell 
lines. All cell lines were confirmed to be free of mycoplasma prior to use and were tested 
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every three months. All cell lines were cultured in DMEM/F-12 with GlutaMAX™ 
supplement, 10% tetracycline-free Fetal Bovine Serum (Clontech), and 100 units/ml 
penicillin and 100 μg/ml streptomycin. Lenti-X™ 293T cell line was cultured in DMEM/F-
12 with GlutaMAX™ supplement, 10% tetracycline-free Fetal Bovine Serum (Clontech), and 
100 units/ml penicillin and 100 μg/ml streptomycin.  
 
Generation of Lentivirally Transduced Cell Lines  
Lentivirally-transduced lines were generated using the pLVX-CMV-Tet3G system, detailed 
method is available as an associated file at the GEO database 
https://www.ncbi.nlm.nih.gov/geo/ and assigned the identifier GSE153823. 
 
Proliferation Assays 
Proliferation assays were performed in the Incucyte analysis system (IncuCyte Zoom
TM
 
Videomicroscopy, Essen Bioscience Ltd.). Relative confluency was calculated by comparing 
growth rates of either WT or SA ASCL1 versus uninduced cells. Cell count experiments were 
carried out in parallel to evaluate total cell numbers at different time points. Briefly, cell 
numbers of two independent clones of each of WT and S-A SH-SY5Y were compared to 
uninduced clonal cell lines. (SH-SY5Y cells were induced with 4ng/mL doxycycline over 96 
hours).  
 
Chromatin isolation, Western Blotting and Phos-Tag Western Blot 
Subcellular fractionation was performed using the subcellular protein fractionation kit 
(Thermo Scientific) according to the manufacturer's instructions. Western blot analysis were 
performed as previously described in  (19). ASCL1 phospho-status was determined in 8% 
acrylamide gels polymerised with 20 µM Phos-tag reagent (WAKO) and 40 µM MnCl2. 
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After running and before transfer, phos-tag gels were washed three times, 10 min each with 
transfer buffer (25mM Tris-HCl, 190mM glycine, 20% methanol) plus 10 mM EDTA, 
followed by a final wash with transfer buffer. Antibodies used were: anti-ASCL1 (1:250; a 
kind gift from David Anderson and Francois Guillemot), anti-C-MYC (1:10000; Abcam), 
anti- N-MYC (1:500; Abcam), anti-H3 (1:5000; Abcam),  anti-PARP (1:500; BD) and anti-
GAPDH (1:1000; Sigma) or anti α-tubulin (1:5000; Sigma).  
 
Immunohistochemistry 
Immunohistochemistry was performed as previously described in  (19). Antibodies used were 
anti-β tubulin (TUJ1) (1:1000; Covance) or anti-ASCL1 (1:200; Abcam). 
 
Quantitative Real-Time PCR 
Quantitative real-time PCR was perfomed as previously described in (19). The primer 
sequences are provided in Supplementary Table 1. Relative quantification was determined 
according to the c(t) method. Data are presented as means ± S.E.M. of normalised values. 
 
Chromatin Immunoprecipitation (ChIP), ChIP-Seq  
ChIP and ChIPseq  were performed as described previously (20, 21). Antibodies used were 
anti-ASCL1 (Abcam) and anti-IgG (Abcam). ChiPSeq data and full associated methods are 
both available as an associated file at the GEO database https://www.ncbi.nlm.nih.gov/geo/ 
and assigned the identifier GSE153823. ChIPseq experiments were performed in two 
separate clones of each of WT and S-A SH-SY5Y tetracycline-inducible stable cell lines 
induced with 1 µg/ml doxycycline for 24 hours in four biological replicates. Differential 
binding analysis (Diffbind) was performed as described previously (20). ChIP-qPCR primer 





RNA-sequencing experiments were performed in SH-SY5Y, WT and S-A SH-SY5Y 
tetracycline-inducible stable cell lines, using two clones of each in at least five biological 
replicates for each cell line. Full RNAseq data and methods for RNA-seq are available at the 
GEO database https://www.ncbi.nlm.nih.gov/geo/ and assigned the identifier GSE153823.  
Single-end 50-bp reads generated on the Illumina HiSeq sequencer were aligned to the 
human genome version GRCh37 and read counts were generated using STAR 2.5.1a (22).  
 
Gene Set Enrichment Analysis 
FDR-values derived from DESeq2 analyses of the RNA-Seq data for all selected genes were 
–log10 transformed. These values were subsequently used for ranking and weighting of 
genes.  GSEA Preranked analysis tool from Gene Set Enrichment Analysis (GSEA) software, 
version 2.2.3 (http://software.broadinstitute.org/gsea/index.jsp) has been used for establishing 
potential functional relation in gene expression. 
Quantification and statistical analysis 
Statistical analysis were performed using a two-tailed unpaired student t-test (*P≤0.05, 
**P≤0.01, ***P≤0.001); standard error of the mean (S.E.M.) calculated from at least three 
independent experiments.  
Data availability 
The next generation sequencing data from this publication have been deposited to the GEO 




Elevated ASCL1 activity promotes mitotic exit of neuroblastoma cells 
 Neuroblastoma cells frequently express ASCL1 (15), yet remain highly proliferative. 
As over-expression of ASCL1 can drive ectopic noradrenergic neurogenesis in vivo (15), we 
questioned whether an increase in ASCL1 activity over the endogenous level might be 
sufficient to render neuroblastoma cells post-mitotic and activate morphological 
differentiation. To explore this, we exploited the SH-SY5Y neuroblastoma cell line, which 
expresses a moderate level of ASCL1 protein (15) and is a representative model of the higher 
risk ADRN disease subtype (4, 5) (hereafter NB cells).  Using isogenically matched ASCL1-
inducible NB lines to study the effects of different expression levels (Supplementary Fig. 
S1A) revealed that increasing WT ASCL1 progressively reduced NB cell confluency 
(Supplementary Fig. S1B). Cell apoptosis is accompanied by cleavage of PARP, which can 
be readily observed after SDS PAGE separation in control NB cells treated with the apoptotic 
inducer Staurosporine (Supplementary Fig. S1C).  A PARP cleavage product is absent from 
Dox-treated ASCL1-expressing NB cells, so the reduction in cell number cannot be attributed 
to an increase in apoptosis, but  does indicate that elevating ASCL1 activity supresses NB 
cell proliferation. 
 
 A phosphomutant form of ASCL1 (S-A ASCL1) can be generated by mutating all 
serine-proline phosphorylation sites to alanine-proline.  This phosphomutant form of the 
protein has previously been used to show that preventing multi-site phosphorylation of 
ASCL1 promotes transcription factor-mediated reprogramming of embryonic ectoderm and 
fibroblasts into neurons (18). When expressed in NB cells and detected by western blotting 
after SDS PAGE separation, S-A ASCL1 runs faster than WT ASCL1 but with similar 
mobility to WT ASCL1 that has been exposed to a broad-spectrum phosphatase, 
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(Supplementary Fig. S1D). This indicates that extensive ASCL1 phosphorylation in NB cells 
usually occurs on serine-proline sites and is prevented by introducing phosphorylation site 
mutations.  We next tested whether preventing phosphorylation of ASCL1 on serine-proline 
sites in NB cells affects its ability to potentiate cell cycle exit and differentiation.  
 
Un(der)phosphorylated ASCL1 drives cell cycle exit and differentiation 
 To directly compare the effect of increasing ectopic expression of either wild-type or 
phospho-mutant ASCL1 in NB cells, we induced ASCL1 protein in doxycycline-inducible 
clonal cell lines expressing either WT or S-A ASCL1 (Fig. 1A and Supplementary Figure 
S1B), resulting in nuclear expression of ASCL1  (Supplementary Fig. S1E). When induced at 
similar levels in NB cells, phosphomutant S-A ASCL1 shows greater potency in suppressing 
cell division than WT ASCL1 (Figure 1A left, Supplementary Fig. S1B).  Proliferative arrest 
induced by S-A ASCL1 is accompanied by cell aggregation, and also neurite extension 
normally associated with neuronal differentiation (Fig. 1A, right).  Over-expression of S-A 
ASCL1 also drives neurite extension in BE(2)C cells, a MYCN-amplified neuroblastoma cell 
line, while expression of WT ASCL1 at a similar level does not  (Supplementary Figure 1F). 
 
To understand how un(der)phosphorylated ASCL1 inhibits neuroblastoma proliferation and 
enhances changes associated with differentiation, we interrogated RNAseq data to identify 
changes in expression of selected key regulators 24 hours post WT and SA-ASCL1-
expression, alongside ChIPseq data quantifying ASCL1 binding adjacent to regulated genes.  
S-A ASCL1 binds more effectively that WT ASCL1 to regulatory regions associated with 
several prominent pro-proliferative genes including SKP2, E2F1 and the MYC-target gene 
CDCA7 and also downregulates their expression (Fig. 1B), as further validated by ChIP-
qPCR and real-time PCR analysis (Fig. 1C and 1D).  Other key cell cycle regulators 
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including CDK1 and CDK2 are also highly downregulated by un(der)phosphorylated ASCL1 
(Fig. 1D). 
 
Un(der)phosphorylated ASCL1 inhibits the MYC-driven core regulatory circuit that 
drives neuroblastoma.   
 ADRN-type neuroblastoma is locked into a highly proliferative state by a core 
oncogenic network of transcription factors, representing the “core regulatory circuit” (4, 5).  
This includes the developmental regulators PHOX2B, HAND2 and GATA3 that 
combinatorially activate high level expression of each other and of downstream target genes 
via clusters of regulatory elements called “super-enhancers” (4, 5). Importantly, ASCL1 
binds in proximity to the genomic locations that encode all three of these genes, suggesting 
feed-forward regulatory mechanisms (17).  We investigated the effect of elevated WT or S-A 
ASCL1 on expression of these core regulatory circuit (CRC) genes. Upregulation of WT 
ASCL1 results in a modest suppression of the CRC genes GATA3 and HAND2, while 
having little effect on PHOX2B, whereas S-A ASCL1 induction results in almost total 
suppression of expression of all 3 of these CRC genes (Fig. 2A).   
c-MYC/NMYC binds at super-enhancers associated with the 
PHOX2B/HAND2/GATA3 core regulatory circuit and are associated with particularly high 
levels of gene activation (4). High risk neuroblastoma can have either MYCN amplification 
(23), or alternatively elevated MYC (MYC).  Elevated MYC functions in place of NMYC in 
our  SH-SY5Y NB cell model to maintain their neuroblastic phenotype (24). Consistent with 
a role for NMYC amplification being replaced by MYC activity in SH-SY5Y cells, we see 
that NMYC is cytoplasmic (Supplementary Fig. S2A). Moreover, MYCN is known to be 
directly regulated by ASCL1 in MYCN-amplified cell lines (17), while MYCN gene 
expression is not altered by WT or S-A ASCL1 in NB cells (Supplementary Fig. S2B), which 
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is also consistent with MYC and not MYCN regulating the neuroblastic programme in SH-
SY5Y NB cells. We therefore investigated the effect of ASCL1 on MYC expression and its 
chromatin association in NB cells.  
Both WT and S-A ASCL1 bind the MYC gene locus and S-A ASCL1 in particular 
suppresses MYC expression (Fig. 2A).  S-A ASCL1 induction also results in reduced C-
MYC binding to NB cell chromatin (Fig. 2B and Supplementary Fig. S2C), and consistent 
with this, S-A ASCL1 induction significantly perturbs the expression of hallmark MYC 
target genes (Fig. 2C), as well as downregulating genes associated with cell cycle phase 
transitions (Fig. 2C).   
In addition to suppressing pro-proliferative genes, and the core regulatory circuit that 
maintains the proliferating neuroblastic phenotype, ASCL1 also binds and activates 
expression of the CDK inhibitor CDKN1C (Fig. 3A).  Thus S-A ASCL1 can directly drive 
cell cycle exit by co-ordinated downregulation of the MYC-driven core regulatory circuit that 
maintains neuroblast identity as well as regulating genes that control the cell cycle directly. 
This is in contrast to WT ASCL1 which shows less repressive activity on MYC and other key 
cell cycle target genes. 
 
Decreased proliferation of NB cells could be a consequence of a switch to a pro-
differentiation state.  In support of this hypothesis, we saw that increased ASCL1 activity, 
and particularly that of phospho-mutant S-A ASCL1, results in enhanced binding and 
activation of a wide range of direct targets that have previously been associated with neuronal 
differentiation (Fig. 3A and Supplementary Fig. S3) (25-27),  with further expression 
validation undertaken by ChIP-qPCR and real-time PCR analysis (Fig. 3B and 3C). 
We next explored whether the programme of ASCL1-induced mitotic arrest is 
reversible in SH-SY5Y NB cells.  When S-A ASCL1 was induced at low levels, marked 
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suppression of cell division was observed (Fig. 1A, Supplementary Figure 1B and Figure 
3D).  When we removed doxycycline after 4 days to turn off expression of S-A ASCL1, we 
saw a rapid re-entry into cell cycle (Fig. 3D). However, when S-A ASCL1 was expressed 
continuously for 7 days and then turned off, the re-entry into the cell cycle was substantially 
slower (Fig. 3D), demonstrating that post-mitotic effects of prolonged expression of 
un(der)phosphorylated ASCL1 are relatively durable even after ASCL1 removal. 
 
Discussion  
 ADRN-type neuroblastoma, the most lethal form of the disease, is driven by high 
level expression of the core regulatory circuit of transcription factors including PHOX2B, 
HAND2 and GATA3 (4, 5). These factors are usually transiently expressed in sympathetic 
neuron development, but elevated MYCN and/or MYC results in stabilisation of mutually 
regulated super-enhancers associated with these and other genes that lock cells in a pro-
proliferative neuroblastic phenotype (6, 24). Indeed, deregulated MYCN has been directly 
shown to invade enhancers of developmentally-regulated genes, locking cells in pre-
established progenitor behaviour epigenetically (7).  Here we show that activation of ASCL1 
by dephosphorylation drives a direct programme of mitotic arrest and gene expression 
changes consistent with differentiation in neuroblastoma cells that carry high levels of MYC, 
as well as promoting cell aggregation and neurite outgrowth (Figure 1A).  High risk disease 
is often associated with MYCN gene amplification and the BE(2)C cell line, representative of 
this class of neuroblastomas, also shows signs of neurite extension in response to 
phosphomutant ASCL1 (Supplementary Figure 1F).  Neuroblastoma is a highly diverse 
disease. It will be important to to further explore ASCL1’s potential as a therapeutic target in 
this devastating disease by determining which subtypes of neuroblastoma respond to 
dephosphorylated ASCL1 by undergoing mitotic exit and differentiation.  
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 ASCL1 is expressed in ADRN-type neuroblastoma (5, 17), where selective pressures 
may favour a level lower of ASCL1 than the threshold required to drive cell cycle exit and 
differentiation (Supplementary Figure S1B). We show enhancing ASCL1 activity by 
dephosphorylation can unlock a latent ability of NB cells to exit the cell cycle and undergo 
differentiation manifested in transcriptional and morphological changes, in part by co-
ordinately downregulating the MYC-driven PHOX2B/GATA3/HAND2 core regulatory circuit 
that drives the pro-proliferative oncogenic ADRN phenotype of NB cells.  In addition, 
un(der)phosphorylated ASCL1 simultaneously directly suppresses pro-proliferative targets 
such as SKP2 and E2F1  and activates the CDK inhibitor CDKN1C,  resulting in exit from 
cell cycle, as well as activating a programme of genes associated with neuronal development 
and differentiation.   
Elevating ASCL1 expression level in the subset of glioblastoma stem cells that usually 
express ASCL1 only at a low level is sufficient to drive stable cell cycle exit  (12).  High 
levels of ASCL1 also impair reversion to a self renewing state even when ASCL1 is 
subsequently turned off  (12), mimicking its normal role in development and pointing to a 
wider ability of ASCL1 to drive a stable state of differentiation in malignant cells.  Our data 
in neuroblastoma cells indicate that activation of ASCL1 may also be achieved by preventing 
its phosphorylation. ASCL1 has been shown to be phosphorylated by cyclin-dependent 
kinases in developing Xenopus embryos (18) and by MAP kinases in glioma cells (28). 
Rapidly proliferating neuroblastoma cells are likely to have high level of both classes of 
kinases, so CDK inhibitors and MAP kinase inhibitors are good candidates, perhaps in 
combination, to drive differentiation of neuroblastomas by dephosphorylation of endogenous 
ASCL1, and it will be important to now test this in vivo.  We also note that investigation of 
trials of CDK4/6-targeted CDKis as therapeutic agents in neuroblastoma are already 
underway  (29) and possible effects on differentiation as well as mitotic exit/cell death should 
 14 
be explored. There is also interest in the therapeutic use of CDK inhibitors that primarily 
target the transcriptional CDKs , CDK7/9  (9).  These appear to bring about cell death by 
targeting the high level expression of the CRC genes and MYCN mediated by high level 
super-enhancer activity. We note that inhibitors that generally repress transcription are very 
likely to impede re-imposition of a differentiation programme, so inhibitors with specificity 
for mitotic CDKs are better candidates for use in therapies designed to promote 
differentiation.  
 Proneural transcription factors are increasingly identified as playing a crucial role in 
lineage-specific oncogenesis. For example, ASCL1 is expressed in a number of tumours 
including neuroblastoma, glioblastoma and small cell lung cancer (11, 13, 15, 16), while 
other proneural proteins act in an oncogenic context in medulloblastoma, and many endocrine 
neoplasias (2, 30). The relative importance of these proneural factors in defining the cell of 
origin and context of oncogenic drivers versus an active role in driving tumorigenicity is 
generally unclear (2), although an active pro-tumorigenic function is likely in some contexts; 
for instance, ASCL1 transcriptionally upregulates oncogenic and anti-apoptotic drivers such 
as MYCL1, SOX2, NF‐IB, and BCL2 in small cell lung cancer (13, 31).   
While, a picture is emerging in multiple cancers of the function of these master 
regulator proneural factors being subverted to promote oncogenesis, their activity in tumours 
still retains echoes of their normal developmental role in controlling the balance between 
proliferation and differentiation (2, 30).  Phosphorylation of proneural proteins is a widely-
conserved regulatory mechanism controlling the differentiation activity of many members of 
this transcription factor family in development (e.g. (18, 19, 32, 33)). In neuroblastoma cells, 
we see that a more normal developmental function of driving differentiation can be re-
imposed on ASCL1 protein by manipulating its post-translational modification.  We propose 
a wider model that the phosphorylation of proneural factors by elevated CDKs and other 
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proline-directed kinases in rapidly dividing cancer cells may act in multiple tumour types to 
profoundly affect the spectrum of proneural target gene expression,  favouring those that 
potentiate stem/progenitor maintenance, rather than those that would drive differentiation.  
Given ASCL1’s role supporting oncogenesis in other cancers (11, 13, 15, 16, 34), and the 
fact that different types of aggressive tumours converge on a neuroendocrine identity that is 
associated with enhanced accessibility of ASCL1-responsive elements (35), it is tempting to 
speculate that inhibiting ASCL1 phosphorylation could be exploited to drive differentiation 
for therapeutic benefit in a range of cancers.  
 
Acknowledgements 
We would like to sincerely thank Sabine Dietmann, Mohammadmersad Ghorbani for help 
with bio-informatic analysis, Geetha Sankaranarayanan for technical support. Carol Thiele, 
Louis Chesler, John Gurdon, Guy Blanchard, Clive DeSantos, Eva Papachristou and all 
Philpott lab members for helpful discussions. We would like to thank Prof. Deborah Tweddle 
and Prof. John Hardy for generously supplying the neuroblastoma cell lines. Work was 
supported by Cancer Research UK Programme Grant RG91505 (AP), Wellcome Trust 
Investigator Award 212253/Z/18/Z (AP), MRC Research Grant MR/L021129/1 (F.A, A.P); 
Neuroblastoma UK (D.M, T.P, A.P), CRUK Cambridge Centre Paediatric Programme (L.P), 
The Terry Fox Foundation (FA), MBRU College of Medicine Internal grant award MBRU-
CM-RG2019-14 (FA), MBRU-ALMAHMEED Collaborative Research Award ALM1909 
(FA) and core support from the Wellcome Trust and the MRC Cambridge Stem Cell Institute 






F.A., D.M, L.W and L.P developed experimental protocols, performed and analysed 
experiments with assistance from J.D. I.C. performed bioinformatic analysis. T.P., D.M., and 
L.W. generated the cell lines.  All authors contributed to discussions. A.P. and J.C. directed 





1. Ratner N, Brodeur GM, Dale RC, Schor NF. The "neuro" of neuroblastoma: 
Neuroblastoma as a neurodevelopmental disorder. Ann Neurol. 2016;80(1):13-23. 
2. Azzarelli R, Simons BD, Philpott A. The developmental origin of brain tumours: a 
cellular and molecular framework. Development. 2018;145(10). 
3. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the 
mechanisms of cure. Nat Rev Cancer. 2010;10(11):775-83. 
4. Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugene C, Raynal V, et al. 
Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat 
Genet. 2017;49(9):1408-13. 
5. van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, et al. 
Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat 
Genet. 2017;49(8):1261-6. 
6. Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey 
N, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core 
transcriptional regulatory circuitry. Nat Genet. 2018;50(9):1240-6. 
7. Zeid R, Lawlor MA, Poon E, Reyes JM, Fulciniti M, Lopez MA, et al. Enhancer invasion 
shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat Genet. 
2018;50(4):515-23. 
8. van Groningen T, Akogul N, Westerhout EM, Chan A, Hasselt NE, Zwijnenburg DA, et 
al. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal 
state in neuroblastoma. Nat Commun. 2019;10(1):1530. 
9. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. 
CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven 
cancer. Cell. 2014;159(5):1126-39. 
10. Castro DS, Martynoga B, Parras C, Ramesh V, Pacary E, Johnston C, et al. A novel 
function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide 
characterization of its targets. Genes Dev. 2011;25(9):930-45. 
11. Rheinbay E, Suva ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, et al. An 
aberrant transcription factor network essential for Wnt signaling and stem cell maintenance 
in glioblastoma. Cell Rep. 2013;3(5):1567-79. 
12. Park NI, Guilhamon P, Desai K, McAdam RF, Langille E, O'Connor M, et al. ASCL1 
Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of 
Glioblastoma Stem Cells. Cell Stem Cell. 2017;21(2):209-24 e7. 
13. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: 
implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549-61. 
14. Ayrault O, Zhao H, Zindy F, Qu C, Sherr CJ, Roussel MF. Atoh1 inhibits neuronal 
differentiation and collaborates with Gli1 to generate medulloblastoma-initiating cells. 
Cancer Res. 2010;70(13):5618-27. 
15. Wylie LA, Hardwick LJ, Papkovskaia TD, Thiele CJ, Philpott A. Ascl1 phospho-status 
regulates neuronal differentiation in a Xenopus developmental model of neuroblastoma. Dis 
Model Mech. 2015;8(5):429-41. 
16. Kasim M, Hess V, Scholz H, Persson PB, Fahling M. Achaete-Scute Homolog 1 
Expression Controls Cellular Differentiation of Neuroblastoma. Front Mol Neurosci. 
2016;9:156. 
 18 
17. Wang L, Tan TK, Durbin AD, Zimmerman MW, Abraham BJ, Tan SH, et al. ASCL1 is a 
MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory 
circuitry. Nat Commun. 2019;10(1):5622. 
18. Ali FR, Cheng K, Kirwan P, Metcalfe S, Livesey FJ, Barker RA, et al. The 
phosphorylation status of Ascl1 is a key determinant of neuronal differentiation and 
maturation in vivo and in vitro. Development. 2014;141(11):2216-24. 
19. Ali F, Hindley C, McDowell G, Deibler R, Jones A, Kirschner M, et al. Cell cycle-
regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with 
differentiation during neurogenesis. Development. 2011;138(19):4267-77. 
20. Jozwik KM, Chernukhin I, Serandour AA, Nagarajan S, Carroll JS. FOXA1 Directs H3K4 
Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3. Cell Rep. 
2016;17(10):2715-23. 
21. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. ChIP-seq: using 
high-throughput sequencing to discover protein-DNA interactions. Methods. 
2009;48(3):240-8. 
22. Anders S, Huber W. Differential expression analysis for sequence count data. 
Genome Biol. 2010;11(10):R106. 
23. Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 
2013;3(10):a014415. 
24. Zimmerman MW, Liu Y, He S, Durbin AD, Abraham BJ, Easton J, et al. MYC Drives a 
Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms 
Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discov. 
2018;8(3):320-35. 
25. Constantinescu R, Constantinescu AT, Reichmann H, Janetzky B. Neuronal 
differentiation and long-term culture of the human neuroblastoma line SH-SY5Y. J Neural 
Transm Suppl. 2007(72):17-28. 
26. Kovalevich J, Langford D. Considerations for the use of SH-SY5Y neuroblastoma cells 
in neurobiology. Methods Mol Biol. 2013;1078:9-21. 
27. Shipley MM, Mangold CA, Szpara ML. Differentiation of the SH-SY5Y Human 
Neuroblastoma Cell Line. J Vis Exp. 2016(108):53193. 
28. Li S, Mattar P, Dixit R, Lawn SO, Wilkinson G, Kinch C, et al. RAS/ERK signaling 
controls proneural genetic programs in cortical development and gliomagenesis. J Neurosci. 
2014;34(6):2169-90. 
29. Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, et al. A Phase 
I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant 
Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 
2017;23(10):2433-41. 
30. Huang C, Chan JA, Schuurmans C. Proneural bHLH genes in development and 
disease. Curr Top Dev Biol. 2014;110:75-127. 
31. Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, et al. ASCL1 is a 
lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. 
Proc Natl Acad Sci U S A. 2014;111(41):14788-93. 
32. Azzarelli R, Hurley C, Sznurkowska MK, Rulands S, Hardwick L, Gamper I, et al. Multi-
site Neurogenin3 Phosphorylation Controls Pancreatic Endocrine Differentiation. Dev Cell. 
2017;41(3):274-86 e5. 
 19 
33. Tomic G, Morrissey E, Kozar S, Ben-Moshe S, Hoyle A, Azzarelli R, et al. Phospho-
regulation of ATOH1 Is Required for Plasticity of Secretory Progenitors and Tissue 
Regeneration. Cell Stem Cell. 2018;23(3):436-43 e7. 
34. Rapa I, Volante M, Migliore C, Farsetti A, Berruti A, Vittorio Scagliotti G, et al. Human 
ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and 
interferes with androgen responsiveness in prostate cancer cells. Prostate. 
2013;73(11):1241-9. 
35. Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, et al. Reprogramming 
normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. 
Science. 2018;362(6410):91-5. 
 
Figure Legends  
Fig 1: ASCL1 expression and phosphorylation regulates NB cell proliferation 
(A) Cell count assay of WT versus S-A ASCL1 NB cells after doxycycline induction at 
4ng/ml, n=3 biological replicates. Graph shows Mean ± SEM, two-tailed unpaired t-test 
(***p<0.001) [Left]. Cell clustering and neurite outgrowth (white arrow heads) after WT 
and S-A ASCL1 induction. Tuj1 staining (Green), DAPI (Blue) [Right]. 
(B) ChipSeq and RNAseq tracks of pro-proliferative targets SKP2, E2F1 and CDCA7 in NB 
cells, either uninduced (Ctl) or 24 hours post-induction of WT and S-A ASCL1. ChipSeq 
n=8 in 4 biological replicates, RNAseq n=10 in 5 biological replicates. 
(C) ChIP qPCR of SKP2, E2F1 and CDCA7 in NB cells 24 hours post-induction of WT and 
S-A ASCL1, n=4 biological replicates. Graph shows Mean ± SEM, two-tailed unpaired t-
test (*** p<0.001). 
(D) qPCR analysis of pro-proliferative targets in NB cells either uninduced (control) or 24 
hours post-induction of WT and S-A ASCL1, n=4 biological replicates. Graph shows 
Mean ± SEM, two-tailed unpaired t-test (*** p<0.001). 
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Fig 2: Dephosphorylated ASCL1 supresses the oncogenic core regulatory circuit of NB 
cells 
(A) ChIPseq and RNAseq tracks of PHOX2B, GATA3, HAND2 and MYC in NB cells, either 
uninduced (Ctl) or 24 hours post-induction of WT and S-A ASCL1. ChipSeq n=8 in 4 
biological replicates, RNAseq n=10 in 5 biological replicates. 
(B) Western blotting for MYC within the cytoplasm and chromatin fractions either uninduced 
(Ctl) or 24 hours post-induction of WT and S-A ASCL1, GAPDH (control for 
cytoplasmic fractionation) and histone H3 (control for chromatin fractionation). 
(C) Gene set enrichment analysis (GSEA Preranked) of downregulated gene sets after an  
evaluated differential gene expression test of S-A ASCL1 versus uninduced cells. The 
ranked gene list was tested against Hallmarks or Gene Ontology set from the GSEA 
database.  
 
Fig 3: Dephosphorylated ASCL1 unlocks a latent ability of NB cells to differentiate 
(A) ChipSeq and RNAseq tracks of differentiation targets in NB cells, either uninduced (Ctl) 
or 24 hours post-induction of WT and S-A ASCL1. ChipSeq n=8 in 4 biological 
replicates, RNAseq n=10 in 5 biological replicates. 
(B) ChIP qPCR of differentiation targets in NB cells 24 hours post-induction of WT and S-A 
ASCL1, n=4 biological replicates. Graph shows Mean ± SEM, two-tailed unpaired t-test 
(*p<0.05, **p<0.01, *** p<0.001)  
(C) qPCR analysis of differentiation targets in NB cells either uninduced (control) or 24 hours 
post-induction of WT and S-A ASCL1, n=4 biological replicates. Graph shows Mean ± 
SEM, two-tailed unpaired t-test (*** p<0.001). 
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(D) Cell count after S-A ASCL1 induction by addition of 4ng doxycycline for 96 hrs or 7 
days as labelled, doxycycline removed for 1, 3 and 7 days, as labelled. n=6 in 3 biological 
replicates. Graph shows Mean ± SEM, two-tailed unpaired t-test. (**p < 0.01). 
 



List of primers used in  gene expression qPCR experiments
Gene Primer forward (5’‐3’) Primer reverse (5’‐3’)
NTRK1 TTGCCTGCCTCTTCCTTTCTAC ATTGTGGGTTCTCGATGATGTG
DBN1 GAGGAAACTGAGGCAAAGAGGA TCGGAGCCATCTTCATATGTGT
ADRA2C GAGTACAACCTGAAGCGCACAC GGAGGACAGGATGTACCAGGTC
NKD1 AAGAGGAGCGTCCTTGTCAATC CCGGCGAGATCTAAGTAGTGGT
CDKN1C GAGCCAATTTAGAGCCCAAAGA AAGCTTTACACCTTGGGACCAG
RET TAGCTCCTGGGAGAAGCTCAGT GGAAAGGAGGTGTTGAAGAAGG
TUBB3 TCAGCAAGGTGCGTGAGGAG GAGGGTGCGGAAGCAGATGT
MAP2 TTCTGCGCCCAGATTTTATTGA GCTCCCAATCAATGCTTCCT
DBH TCAACAACGAGGATGTCTGC CAGTGTGGAGATGACCTTGG
CDK1 GGCCTTGCCAGAGCTTTTGGAATA AGTGGTTTCTTAGTTGCTAGTTCAGC
CDK2 TACCGAGCTCCTGAAATCCTCCT CGGAAGAGCTGGTCAATCTCAGAAT
SKP2 CCACGGAAACGGCTGAAGAGCA CAAACACCAGAGACCTTTAGCAGCT
E2F1 TGACATCACCAACGTCCTTGAGG CTGTCGGAGGTCCTGGGTCAA
FOXM1 GTGAATCTTCCTAGACCACCTGGA GTGACAATTCTCCTTTTCCTCCATCT
BIRC5 CATTCGTCCGGTTGCGCTTTCC CGGCGCACTTTCTCCGCAGTTT
CDCA7 ACGAACTGGCCGGTATTTTTCATGC GGTACTCCGCGCTGGAAACTTC
KI67 GAGGTGTGCAGAAAATCCAAA CTGTCCCTATGACTTCTGGTTGT
PHOX2B TTCACCAGTGCCCAGCTCAAAGA TTGCCCGAGGAGCCGTTCTTG
GATA3 CCAGCACAGAAGGCAGGGAGT CTGTCCGTTCATTTTGTGATAGAGCC
HAND2 ATACGAAGAGGACACTCCCG GGACCTGATGACTTTCTCCC
TBP GAGCTGTGATGTGAAGTTTCC TCTGGGTTTGATCATTCTGTAG
List of primers used in Chip‐qPCR experiments
Gene Primer forward (5’‐3’) Primer reverse (5’‐3’)
SKP2 TGGCCCTTGGAGTGAGTGTATG ATTGTCCCCTTTCCGCCTGTTA
E2F1 GCCTTCACTTCCCCTAGCAGCT GTGGTGGGGCTGGGATTTGAAC
CDCA7 GGTCTTGCGAACCGGTCTCCTA AAATGCACTTAACCACCGCCCG
NTRK1 GATGACCTGGACAGCAACCTTT GCATTTTTACATTTGGGGAGGA
DBN1 GAGAAGCAGAGGGAGAAACCAG TGTCCCTTCACTTCTGTCCTTTC
ADRA2C CACATGTGCTAATGCTCACACC TGTATCTCCCCACCTGTGTCTG
NKD1 CTTAACAGAGAGGAGGCCCTGA CAGAGACGTCCAAATGACTTGC
CDKN1C AGCTTTACACCTTGGGACCAGT GACCGTTCATGTAGCAGCAACC
RET CTGATTCCAAAATGAGCACAGG CCCCAAGTGCTAGGATTACAGG
DBH CCGCCTGTCTACTTCAACTCC  TGTACATGAAGGCTGCCTCC 
PHOX2B  CTTGCTAATGTCTCTGCCTGCG AGACGCATAGAAACACCCACCA
GATA3  GCAGGGTAAGATGTCCAAAGCC GGTGAGTGGAAAGGAATTGGAGTC
HAND2  ACTGGAGTTGGAATGAGGCATCT CTAAGGCTTTCGTGGGGCAATG
